ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 709,75
0,98%
Dow Jones
43 487,83
0,78%
DAX
20 903,39
1,31%
Brent Oil
80,005
0,00%
Bitcoin
104 171,95
0,04%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Protara Therapeutics Inc (TARA)

  7. Protara Therapeutics Inc (TARA) Actualités

TARA

Protara Therapeutics (TARA)

Protara Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:TARA
DateHeureSourceTitreSymboleSociété
13/01/202522h34Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TARAProtara Therapeutics Inc
13/01/202514h00GlobeNewswire Inc.Protara Highlights Recent Updates and Anticipated 2025 MilestonesNASDAQ:TARAProtara Therapeutics Inc
08/01/202514h00GlobeNewswire Inc.Protara Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:TARAProtara Therapeutics Inc
07/01/202522h20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TARAProtara Therapeutics Inc
17/12/202422h02Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:TARAProtara Therapeutics Inc
11/12/202422h05GlobeNewswire Inc.Protara Announces Closing of $100 Million Public OfferingNASDAQ:TARAProtara Therapeutics Inc
10/12/202405h35GlobeNewswire Inc.Protara Announces Pricing of $100 Million Public OfferingNASDAQ:TARAProtara Therapeutics Inc
09/12/202422h17Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:TARAProtara Therapeutics Inc
09/12/202422h01GlobeNewswire Inc.Protara Announces Proposed Public OfferingNASDAQ:TARAProtara Therapeutics Inc
05/12/202413h00GlobeNewswire Inc.Protara Announces Positive Results from the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBCNASDAQ:TARAProtara Therapeutics Inc
15/11/202423h52GlobeNewswire Inc.Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic OncologyNASDAQ:TARAProtara Therapeutics Inc
14/11/202418h19Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:TARAProtara Therapeutics Inc
12/11/202414h10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TARAProtara Therapeutics Inc
12/11/202414h00GlobeNewswire Inc.Protara Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business UpdateNASDAQ:TARAProtara Therapeutics Inc
06/11/202414h00GlobeNewswire Inc.Protara Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation ConferenceNASDAQ:TARAProtara Therapeutics Inc
21/10/202414h00GlobeNewswire Inc.Protara Therapeutics Granted FDA Fast Track Designation for Intravenous Choline Chloride for Patients Receiving Parenteral SupportNASDAQ:TARAProtara Therapeutics Inc
09/09/202414h05GlobeNewswire Inc.Protara Therapeutics Announces Completion of First Cohort in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic MalformationsNASDAQ:TARAProtara Therapeutics Inc
09/09/202414h00GlobeNewswire Inc.Protara Therapeutics Announces Results from THRIVE-1, a Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral SupportNASDAQ:TARAProtara Therapeutics Inc
03/09/202414h00GlobeNewswire Inc.Protara Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceNASDAQ:TARAProtara Therapeutics Inc
06/08/202422h16Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:TARAProtara Therapeutics Inc
06/08/202414h00GlobeNewswire Inc.Protara Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business UpdateNASDAQ:TARAProtara Therapeutics Inc
24/06/202423h06GlobeNewswire Inc.Protara Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:TARAProtara Therapeutics Inc
21/05/202414h00GlobeNewswire Inc.Protara Therapeutics to Present at the TD Cowen 5th Annual Oncology Innovation SummitNASDAQ:TARAProtara Therapeutics Inc
10/05/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:TARAProtara Therapeutics Inc
09/05/202422h31Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:TARAProtara Therapeutics Inc
02/05/202414h00GlobeNewswire Inc.Protara Therapeutics Announces First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:TARAProtara Therapeutics Inc
05/04/202414h04GlobeNewswire Inc.Protara Therapeutics Announces Oversubscribed $45 Million Private Placement FinancingNASDAQ:TARAProtara Therapeutics Inc
05/04/202414h02GlobeNewswire Inc.Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral NutritionNASDAQ:TARAProtara Therapeutics Inc
05/04/202414h00GlobeNewswire Inc.Protara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBCNASDAQ:TARAProtara Therapeutics Inc
13/03/202413h00GlobeNewswire Inc.Protara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:TARAProtara Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:TARA

Dernières Valeurs Consultées

EU
PX4
SBF 120
EU
GLE
Societe Generale
NYSE
KO
Coca Cola
EU
BN
Danone
NYSE
JPM
JP Morgan Chase
EU
BNP
BNP Paribas
EU
VK
Vallourec
NASDAQ
MSFT
Microsoft
USI
USTECH100
US Tech 100
EU
EN
Bouygues
COIN
ADAUSD
Cardano
NYSE
DIS
Walt Disney
EU
CS
Axa
EU
AI
Air Liquide
NASDAQ
AAPL
Apple
NASDAQ
GOOGL
Alphabet
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés